Myriad Porter's Five Forces Analysis
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Myriad Bundle
Don't Miss the Bigger Picture
Myriad’s Porter's Five Forces snapshot highlights competitive intensity, supplier leverage, buyer power and substitute threats, revealing where margins and growth may be constrained. It surfaces key strategic risks and opportunistic footholds for value creation. This brief preview only scratches the surface. Unlock the full Porter's Five Forces Analysis to explore Myriad’s competitive dynamics and market pressures in detail.
Suppliers Bargaining Power
Concentrated sequencing and reagent vendors
Core inputs—NGS instruments, chips and proprietary reagents—are concentrated: short‑read market leaders like Illumina account for roughly three‑quarters of the installed base, giving suppliers strong pricing leverage and raising switching costs. Platform lock‑in binds assay chemistry and workflows and long validation cycles (often 6–18 months) deter rapid vendor changes. Volume commitments and co‑development agreements are routinely used to secure discounts and supply stability.
Specialized bioinformatics and cloud dependencies
Variant calling pipelines, annotation databases and secure cloud compute are core and hard to substitute; a single human genome produces ~200 GB of raw data and 2024 cloud analysis workloads drive storage/compute spend sharply upward. Licensing and cloud bills can scale from thousands to millions annually as test volumes grow, compliance narrows vendor choice, and building in-house alternatives demands scarce bioinformatics talent (median US salary ~110,000 in 2024) and multi‑year effort.
Biobanking, sample collection, and logistics
Cold-chain couriers, kit manufacturers and collection-site partners materially affect Myriad’s turnaround time and sample quality; the global cold-chain market topped $300 billion in 2024, concentrating leverage in large providers. Disruptions or price hikes can compress margins and degrade service levels—validation of alternate vendors typically takes 6–12 months, slowing response. Geographic coverage and >90% reliability from established logistics firms amplify supplier bargaining power.
Skilled scientific and clinical labor
- Workforce scarcity: high
- Wage pressure: median tech $62k (BLS May 2024)
- Genetic counselors: ~$85k (NSGC 2024)
- Hiring lag: certification delays
- Dependency: knowledge concentrated in few
Reference data and content providers
Access to curated variant databases, guidelines, and decision-support content directly affects report quality; public repositories like ClinVar surpassed 1.5 million variant submissions by 2024, while proprietary datasets often command premium licensing. Data-use restrictions and multi-year contracts (commonly 3–5 years) can lock pricing and limit portability, raising operating costs and vendor dependence.
- Licensing cost pressure
- Data portability limits
- 3–5 year lock-in
- Public vs proprietary gap (ClinVar >1.5M entries 2024)
Concentrated NGS supply, rising cloud costs and talent shortages squeeze genomics margins
Core inputs are concentrated (Illumina ~75% installed base) creating pricing leverage and long validation cycles (6–18 months). Cloud and bioinformatics scale fast (≈200 GB raw/genome; cloud costs scale to thousands–millions annually) and skilled staff scarcity raises wages (lab tech median $62k; genetic counselors ~$85k in 2024). Cold‑chain market >$300B (2024) and ClinVar >1.5M entries increase supplier dependence.
| Supplier | Metric | 2024 value |
|---|---|---|
| NGS vendors | Market share | Illumina ~75% |
| Genome data | Raw size | ~200 GB/genome |
| Cold‑chain | Market size | >$300B |
| Lab tech | Median wage | $62,000 |
| Genetic counselors | Median wage | ~$85,000 |
| Variant DB | ClinVar entries | >1.5M |
What is included in the product
Detailed Word Document
Tailored Porter's Five Forces analysis for Myriad that uncovers competitive drivers, buyer and supplier power, substitutes and entry threats, and highlights disruptive forces and strategic levers.
Customizable Excel Spreadsheet
A one-sheet, customizable Porter's Five Forces template that visualizes competitive pressure with an instant radar chart, requires no macros, supports scenario tabs (pre/post regulation, new entrants), and is ready to drop into pitch decks or integrate with broader Excel dashboards.
Customers Bargaining Power
Payer concentration and coverage policies
Commercial insurers, Medicare programs and large PBMs set reimbursement rates and utilization rules that materially shape Myriad’s volumes; top three PBMs control roughly 80% of the US PBM market and Medicare Advantage enrollment reached about 50% of beneficiaries in 2024. Coverage determinations can rapidly spur or suppress demand, while prior authorization adds administrative friction and increases price sensitivity. Volume concentration among payers amplifies negotiation leverage against Myriad.
Provider systems and oncology networks
Integrated delivery networks and the 72 NCI-designated cancer centers in 2024 control substantial oncology test volumes, shaping referral flows. Formularies, clinical pathways and lab stewardship programs increase price scrutiny and gatekeep molecular test adoption. Inclusion in system care protocols is pivotal for access, while large accounts routinely negotiate contracted discounts and service-level agreements.
Clinician switching costs and preferences
Oncologists, OB/GYNs and psychiatrists prioritize turnaround time, report clarity and practice support; once Myriad is embedded in EHRs and lab workflows switching costs rise and price sensitivity falls, though decisive head-to-head clinical utility data or guideline changes can drive churn. Robust education and field liaison programs materially increase clinician stickiness and referral continuity.
Patient advocacy and out-of-pocket exposure
Patients increasingly shop on cost as list prices for hereditary and companion genetic tests range roughly 1,000–3,000 and many face deductibles above 1,000, making price salient; financial-assistance programs and advocacy groups push payers and labs for broader, lower‑cost access, while DTC ordering modestly increases buyer choice but still depends on payer coverage for affordability.
- Price salience: list prices 1,000–3,000
- High deductibles: many >1,000
- Advocacy: drives coverage/price pressure
- DTC: raises choice but relies on payers
Global labs and reference partners
Global labs and reference partners aggregate demand across markets, giving them leverage to negotiate transfer pricing amid currency, regulatory and reimbursement complexity; alternatives in many countries increase buyer mobility and pressure on margins. Co-branded offerings and shared investments by partners can rebalance power by aligning incentives and spreading commercialization costs, improving Myriad’s bargaining position.
- Aggregation increases buyer leverage
- FX, regulation, reimbursement drive price negotiation
- Market alternatives raise switching power
- Co-branding shares risk and reduces buyer pressure
PBM and Medicare Advantage sway reimbursement; patients face $1,000–$3,000 test bills
Concentrated payers (top‑3 PBMs ~80%) and Medicare Advantage (~50% enrollment in 2024) set reimbursements and drive volume, giving them strong leverage over Myriad. Large IDNs and 72 NCI centers control referral flows and negotiate discounts; clinicians' EHR integration raises switching costs. Patients face list prices $1,000–$3,000 and common deductibles >$1,000, increasing price sensitivity.
| Metric | Value (2024) |
|---|---|
| Top‑3 PBM share | ~80% |
| Medicare Advantage enrollment | ~50% |
| List price (genetic tests) | $1,000–$3,000 |
| NCI cancer centers | 72 |
Same Document Delivered
Myriad Porter's Five Forces Analysis
This preview of the Myriad Porter's Five Forces Analysis is the exact, fully formatted document you will receive upon purchase—no placeholders or mockups. It is the final, professionally written analysis, ready for immediate download and use. What you see here is what you get.
Rivalry Among Competitors
Dense field in oncology and women’s health
Multiple specialized and full-service labs (hereditary panels, MRD, prenatal) fiercely compete in oncology and women’s health as the global genetic testing market reached an estimated $29.5B in 2024; competition centers on panel breadth and turnaround. Differentiation depends on clinical evidence, guideline inclusion, and physician support, with published outcomes driving referrals. Price pressure appears as panels commoditize, while brand trust and peer-reviewed results reduce churn.
Speed, accuracy, and service as battlegrounds
Turnaround time (commonly 3–14 days for clinical NGS workflows), analytic sensitivity (>99.9% for high‑quality NGS), and variant interpretation quality (VUS rates for multigene panels typically 10–30% industrywide in 2024) directly drive market share; decision‑support tools and access to genetic counseling shape clinician preference, while operational excellence and low redraw rates serve as tie‑breakers and service‑level guarantees intensify rivalry.
Data scale and learning effects
Larger variant databases and linked outcomes—ClinVar reached about 1.9 million submissions in 2024 and public/private cohorts now include hundreds of thousands of genomes—sharpen clinical interpretation and product utility. Firms owning longitudinal datasets compound advantages as iterative learning improves variant classification and monetizable algorithms. Rivals channel substantial R&D and real-world evidence programs, and strong network effects raise adoption thresholds for latecomers, sustaining intense head-to-head competition.
Adjacency moves and bundling
- Bundling: oncology + women’s health + PGx
- Cross-sell: health systems = higher retention
- Pricing: platform discounts squeeze single tests
- Partnerships: pharma/pathway programs raise stakes
Regulatory and IP dynamics
Evolving LDT oversight and stricter IVD approval pathways raise development timelines and capital requirements, shifting competitive rivalry toward players with regulatory experience. Method patents now offer limited protection; proprietary clinical data and operational know-how drive defensibility. Cleared tests function as marketing credentials while compliance complexity advantages scaled incumbents.
- Regulatory burden favors scale
- Data > method patents
- Clearance = commercial moat
Data-rich labs win as genetic testing hits $29.5B on speed, cost and interpretation
Fierce rivalry in oncology and women’s health tests centers on evidence, turnaround and proprietary data as the genetic testing market hit $29.5B in 2024; ClinVar ~1.9M submissions sharpen interpretation. Price pressure and bundling (Myriad FY2024 revenue $632M) favor scale and data-rich incumbents.
| Metric | 2024 |
|---|---|
| Market size | $29.5B |
| ClinVar submissions | ~1.9M |
| Myriad revenue | $632M |
| Turnaround | 3–14 days |
| VUS rate | 10–30% |
SSubstitutes Threaten
Non-genomic diagnostics and imaging
Imaging, pathology and protein biomarkers can guide risk and treatment without genomics; imaging accounted for a core share of diagnostic spend in 2024 (global imaging market ~35 billion USD) and many protein assays run <200 USD versus multigene panels at 1,000–4,000 USD, leading clinicians to favor familiar, reimbursed workflows over genomic testing.
Family history and clinical risk models
Family-history and clinical risk models (Gail, BOADICEA, BRCAPRO) can triage referrals without molecular testing, limiting test demand in borderline cases. In lower-risk groups, where BRCA1/2 prevalence is ~0.2–0.3% versus ~2.5% in Ashkenazi Jews, models often suffice. Reduced adoption hits Myriad in low-yield markets. Guideline shifts (broader testing criteria in recent years) will decide when genomics displaces heuristics.
Pharmacotherapy trial-and-error
Clinicians in mental health commonly adjust antidepressants and antipsychotics empirically rather than using pharmacogenomics, with 2024 surveys reporting clinician PGx uptake under 30%. Payer reimbursement remains inconsistent, limiting use and anchoring trial-and-error prescribing patterns. Perceived variability in patient benefit sustains the substitute despite available tests. Strong, reproducible outcomes and payer coverage increases are required to displace entrenched habits.
Alternative genomic platforms
- Liquid biopsy market ~USD 3.0B (2024)
- Blood-based favored for monitoring/recurrence
- Patient comfort and sampling ease drive substitution
- Fast innovation increases modality-switch risk
Companion diagnostics from pharma
Drug-specific companion diagnostics from pharma can narrow hospital test choices to the approved assay, and by 2024 over 50 FDA-approved CDx existed, solidifying therapy-linked testing. Hospitals often default to CDx bundled in care pathways, which sidelines broader NGS panels and reduces Myriad's addressable hospital market. Contracting terms and label requirements for drugs and CDx further entrench the substitute and raise switching costs.
Imaging ~35B, blood assays & biopsy up; PGx 30%
Imaging (global ~35B USD 2024) and low-cost protein assays (<200 USD) outcompete panels (1,000–4,000 USD). Liquid biopsy (~3.0B USD 2024) and proteogenomics grow fast, favoring blood-based monitoring. PGx clinician uptake <30% (2024) and >50 FDA CDx (2024) anchor therapy-linked assays.
| Metric | 2024 |
|---|---|
| Imaging market | ~35B USD |
| Liquid biopsy | ~3.0B USD |
| PGx uptake | <30% |
| FDA CDx | >50 |
Entrants Threaten
Regulatory and quality barriers
CLIA and CAP accreditation—with about 260,000 CLIA-certified labs and CAP accrediting over 8,000 laboratories in 2024—plus potential FDA oversight of LDTs create steep compliance hurdles. Required validations, proficiency testing and QMS buildouts demand months and substantial capital, raising failure risk for new entrants. Tightened FDA/CMS rules would further raise entry costs and deter scale-up.
Capital intensity and scale economics
NGS labs require expensive capital—high-throughput sequencers list up to about $985,000 (NovaSeq 6000) plus automation and bioinformatics platforms—driving large upfront investment. Unit costs decline sharply with volume, with many targeted panels reaching per-sample economics under $200 at scale, disadvantaging small entrants. Dedicated sales, genetic counseling and medical affairs teams add fixed payroll and operational costs often in the high hundreds of thousands annually. Commercial scale and payer coverage commonly take 12–24 months, creating significant cash burn before reimbursement traction.
Data moats and clinical evidence
Incumbents like Myriad have proprietary variant databases built since BRACAnalysis launched in 1996, creating hard-to-replicate data moats and outcomes evidence. Publications, guideline citations and KOL relationships amplify credibility, requiring entrants to run multi-year prospective studies to achieve similar adoption. Without longitudinal datasets, new offerings suffer impaired interpretation quality and higher VUS rates.
Payer contracts and channel access
Securing favorable coverage and network status is slow and uncertain; Medicare Advantage enrollment reached about 49% of beneficiaries in 2024, intensifying payer leverage. Health systems favor vetted vendors embedded in EHRs and clinical pathways—over 95% of hospitals use certified EHRs—so integration is a gatekeeper. Prior authorization friction disproportionately penalizes unknown brands, and without payer contracting pricing power and referral volumes remain weak.
- Gatekeeping: EHR integration required
- Payer leverage: MA ~49% (2024)
- Prior auth: higher friction for new brands
- No contract = limited pricing & volume
IP, partnerships, and ecosystem ties
Broad method patents give limited protection, but targeted IP and exclusive collaborations—especially with pharma, pathway committees, and advocacy groups—create practical entry barriers for Myriad in 2024; exclusive data-sharing deals further constrain differentiation and pricing power. Building comparable alliances requires years of trust, regulatory navigation, and measurable clinical evidence, raising upfront costs and time to market. New entrants face slow credibility accumulation before commercial traction.
Regulatory and capital barriers plus payer power and data moats block new genomic entrants
Steep regulatory and accreditation hurdles (≈260,000 CLIA labs; CAP >8,000 in 2024) plus potential FDA LDT oversight raise time and cost to entry. High capital: NovaSeq 6000 ≈ $985,000 and bioinformatics/automation drive scale economics. Incumbent data moats (Myriad BRACAnalysis since 1996) and payer leverage (Medicare Advantage ~49% in 2024) limit challenger access.
| Barrier | 2024 metric | Impact |
|---|---|---|
| Accreditation | CLIA ~260k; CAP >8k | Long, costly compliance |
| Capital | NovaSeq ~$985k | High upfront capex |
| Data moat | BRACAnalysis since 1996 | Hard to replicate |
| Payer | MA ~49% | Contracting power |